Research
Energy balance
Cagrilintide-semaglutide resulted in a mean percent change in body weight of -20.4% from baseline to week 68 compared to -3.0% with placebo.
Cagrilintide-semaglutide may be an effective treatment option for significant weight loss in adults with overweight or obesity.
StrongSupportsmedium confidence
The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo.
Why this rating
Based on a phase 3a, multicenter, double-blind, placebo-controlled trial.
Source
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
W. Timothy Garvey et al. · New England Journal of Medicine · 2025
rct · n=3417Cited 138×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →